Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine versus placebo (and paroxetine) in acute bipolar depression
2004-004909-16Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quetiapine in bipolar disorder (BD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in MADRS total score from randomisation to Week 8. Started Mar 2005; status: completed.
02
Drugs
quetiapine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2004-004909-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004909-16.